Get started

Stockanalysis

PayPal (PYPL) - Approaching Potential Reversal ZonePayPal has reached our anticipated zone for Wave (ii), respecting the $59 to $57 range. The price action suggests a possible bottom formation, making it a candidate for a potential entry point. Key observations indicate that the support and reversal zone between $59 and $57 has held and build an EQL there, indicating a possible end to the correction phase. If the price revisits the Point of Control, it could offer another attractive entry point for long-term positions. However, PayPal remains in a range, making the situation somewhat risky as it hasn't broken out decisively yet. There is a risk that the price could revisit the lower bound around $55.77. Falling below this level would invalidate our bullish outlook. We are monitoring PayPal closely and will consider entering long positions if the current support holds and the price action confirms a reversal. The Point of Control remains a key level to watch for another potential entry.
NASDAQ:PYPLLong
by freeguy_by_wmc
Madrigal Pharmaceuticals (MDGL) AnalysisPioneering Treatments for NASH: Madrigal Pharmaceuticals NASDAQ:MDGL is leading the charge in developing treatments for non-alcoholic steatohepatitis (NASH). Its drug, Rezdiffra, is the only approved treatment for metabolic-associated steatohepatitis (MASH). With ongoing research to expand its indications, Madrigal is well-positioned in a market projected to be worth $12 billion to $35 billion annually. Market Potential and Analyst Outlook: Analysts forecast Rezdiffra’s peak sales could exceed $5 billion, with clinical trials for cirrhosis treatment potentially expanding its market by 2026-2027. Given its innovative treatment, strong market potential, and positive analyst outlook, Madrigal is a compelling investment opportunity. Investment Outlook: Bullish Outlook: We are bullish on MDGL above the $255.00-$257.00 range. Upside Potential: With an upside target set at $430.00-$440.00, investors should consider Madrigal's pioneering drug development and significant market potential as key drivers for future stock appreciation. 📊💊 Monitor Madrigal Pharmaceuticals for promising investment opportunities! #MDGL #BiopharmaGrowth 📈🔍
NASDAQ:MDGLLong
by Richtv_official
Mirum Pharmaceuticals (MIRM) AnalysisAdvancements in Rare Disease Therapies: Mirum Pharmaceuticals NASDAQ:MIRM is advancing in the biopharma sector with a focus on therapies for rare diseases. Recently, Mirum submitted a New Drug Application (NDA) for chenodiol tablets to treat cerebrotendinous xanthomatosis (CTX), following positive phase 3 RESTORE trial results. FDA approval could be a breakthrough for early diagnosis and treatment of this rare disease. Positive Market Response: CEO Chris Peetz highlighted the potential impact of chenodiol in alleviating CTX symptoms. Wall Street has responded positively, with Citi raising their price target for Mirum to $64 from $38 and maintaining a Buy rating, reflecting confidence in Mirum's pipeline and recent updates on volixibat and FDA-approved Livmarli. Investment Outlook: Bullish Outlook: We are bullish on MIRM above the $29.00-$30.00 range. Upside Potential: With an upside target set at $48.00-$49.00, investors should consider Mirum's promising pipeline and recent regulatory advancements as key drivers for potential stock appreciation. 📊💊 Monitor Mirum Pharmaceuticals for promising investment opportunities! #MIRM #BiopharmaGrowth 📈🔍
NASDAQ:MIRMLong
by Richtv_official
Intercontinental Exchange (ICE) AnalysisStrategic Moves and Regulatory Tailwinds: Intercontinental Exchange NYSE:ICE is set to benefit from recent SEC regulatory proposals that could shift more trading volume back to public exchanges, enhancing ICE's competitive position. Additionally, ICE's $13 billion acquisition of Black Knight Financial will bolster its presence in the mortgage technology sector, providing comprehensive exposure to the mortgage origination value chain. Investment Outlook: Bullish Outlook: We are bullish on ICE above the $124.00-$125.00 range. Upside Potential: With an upside target set at $195.00-$200.00, investors should consider ICE's strategic acquisitions and favorable regulatory environment as key drivers for potential stock appreciation. 📊🏦 Monitor Intercontinental Exchange for promising investment opportunities! #ICE #MarketGrowth 📈🔍
NYSE:ICELong
by Richtv_official
TSLA | TESLA is OvervaluedTesla, Inc.'s second quarter earnings confirm our view that the stock is one of the most overvalued stocks in the market. Tesla's stock has been rising this year amid a sudden shift in overall market sentiment, with many investors now pricing in a soft-landing scenario after a brutal past year of Federal Reserve rate hikes. But the shift in market sentiment doesn't change the fact that Tesla's stock fundamentals are completely disconnected from reality. Tesla is a terribly overvalued stock that we think is worth closer to $26 per share instead of its current price of about $290 per share. While Tesla is profitable, its profits are nowhere near the levels needed to justify its current valuation. We recognize that Tesla's business generates an impressive return on invested capital (ROIC), which is a key measure of profitability, especially for an automaker. However, that ROIC is already declining in the trailing-twelve-month (TTM) period. Using our reverse discounted cash flow (DCF) model, we find that for the stock to have any upside at current levels, Tesla must improve its ROIC to levels not achieved by even the most profitable businesses in the world . Figure 1 shows Tesla's historical ROIC along with the future ROIC implied by its current stock price. We provide the assumptions behind this DCF scenario later in this report. Tesla's latest earnings continue to show that it is not immune to competitive challenges and will likely see lower profitability in the future. But, its valuation implies the opposite. Any investor with fiduciary duties should be aware of the growing disconnect between Tesla's current fundamentals and the future fundamentals implied by its stock price. Even in an optimistic future cash flow scenario, shares could trade as low as $26/share. All the details are below. Supply Constrained Argument Is Gone: Bulls have long argued that demand for Tesla vehicles has always exceeded the supply of vehicles. However, Tesla's multiple price cuts in 2023, along with its lackluster production levels through the first half of 2023, raise questions about just how much demand there is for Tesla vehicles, especially amid competition from rivals Ford (F), General Motors (GM) and virtually every other automaker. Q2 2023 marks Tesla's fifth consecutive quarter in which vehicles produced were greater than vehicles delivered. Tesla is no longer selling every vehicle it can make. Should demand for EVs slow, Tesla could find itself with higher than wanted inventory levels, which could lead to further price cuts and additional pressure on already falling margins. Continued Cash Burn: Despite Tesla's top line growth, it continues to burn massive amounts of cash. Over the past five years, Tesla has burned a cumulative $4.2 billion in free cash flow (FCF), including $3.6 billion over the trailing-twelve months (TTM) alone. Tesla has generated negative FCF in all but one year (2019) of its existence as a public company. Margin Decline: Tesla's "GAAP gross margin" was 18.2% in 2Q23, down from 19.3% in 1Q23 and 25.0% in 2Q22. 2Q23's GAAP gross margin was below expectations of 18.7% and remains at its lowest level since 4Q20. Tesla's operating margin is also moving the wrong direction as it scales up. After selling 211 thousand more vehicles in 2Q23 compared to 2Q22, Tesla's reported operating margin fell 493 basis points YoY in 2Q23. Tesla noted in its press release that reduced average selling prices were one of the items that impacted margins in the quarter. We would expect Tesla's margins to fall further as competition limits pricing power across the industry. While Tesla has rapidly ramped up vehicle production and deliveries, its market share must increase almost exponentially to justify the expectations baked into its stock price. However, as it stands, Tesla holds a meager share of the global auto industry, and its share of the EV market ranks behind incumbents across Europe and China. In Europe, based on sales from May 2023, Tesla holds a 12% share of the EV market, much lower than VW Group (20%) and Stellantis (STLA) at (14%).In China, also based on sales from May 2023, Tesla holds 9% of the EV market compared to a staggering 38% share for top competitor BYD. Bulls have long argued that Tesla isn't just an automaker, but rather a technology company with multiple verticals such as insurance, solar power, housing, and, yes, robots. We've long refuted these bull dreams. Regardless of the promises of developing multiple business lines, Tesla's business remains concentrated in its auto segment. Auto revenue accounted for 86% of Tesla's TTM revenue as of 2Q23.Tesla can no longer enjoy its first mover advantage as many other major automakers are producing electric vehicles. These competitors have more experience in auto production and more resources and cash flow than Tesla to invest in the electric vehicle market. Tesla is at risk of losing market share to its competitors in the electric vehicle space and its stock price is currently not reflecting that, which is a major risk for investors. Since bottoming out at the beginning of the year, the stock has come up almost 200%, stopping just shy of $300. One could say the recent selloff is due to the earnings, but technical analysis would have suggested that a selloff was due even before the earnings. Firstly, we can see that a significant bearish divergence has been building in the RSI since June. Furthermore, we have been nearing an important area of trade as highlighted by the red rectangle. The $300 level has been a key area of trade, and you’d expect to see some resistance. So if a pullback has begun where can we expect it to end? As I see it, we have formed an initial ABC structure from the lows in wave 1 of a five-wave impulse. This means that wave ii could now take us down to the 61.8% retracement of this rally, which lands us at $198. We can see that this is also a very important area of support, as shown by the Visible Range Volume Profile. And, of course, we have the 200 day Moving Average offering support around this level, too.
NASDAQ:TSLA
by moonypto
Tesla (TSLA): Expecting a Pullback Before the Next RiseIn our livestream a few days ago, we talked about the impressive rise in Tesla's stock. Since our last analysis on June 13th, the stock has jumped 38% in just 19 days. This was somewhat expected because there was a lot of negative sentiment towards Tesla, which often leads to a significant rise. Congratulations to everyone who believed in Tesla with us. Our position is currently profitable, and the stock looks very strong. Current Situation: The current situation shows that Tesla has risen 40 % in less than 25 days, even though there was a lot of negative sentiment. The stock is very strong right now, but a pullback is likely. We think the stock could go up to $256, finishing the sub-wave 3. After hitting this level, we expect a Wave 4 correction, which will give us a chance to make more entries. Strategy: We plan to enter between $217 and $200. We will set the stop-loss at about $198 to protect against a failed Wave 4 scenario. Our strategy involves expecting the Wave 4 correction to close follow-up gaps and retest important levels. Even though the performance is strong, we should be careful as this could still be a temporary rise before another drop (a dead cat bounce). In conclusion, Tesla has shown impressive strength, but we expect a pullback before it goes up further. We are targeting the $256 level for the completion of Wave 3 and plan to enter more between $217 and $200, with a stop-loss at $198. We remain cautiously optimistic and will keep a close eye on the situation.
NASDAQ:TSLALong
by freeguy_by_wmc
6
Voltamp Transformers Limited - Breakout Setup, Move is ON...#VOLTAMP trading above Resistance of 13100 Next Resistance is at 16496 Support is at 9705 Here are previous charts: Chart is self explanatory. Levels of breakout, possible up-moves (where stock may find resistances) and support (close below which, setup will be invalidated) are clearly defined. Disclaimer: This is for demonstration and educational purpose only. This is not buying or selling recommendations. I am not SEBI registered. Please consult your financial advisor before taking any trade.
NSE:VOLTAMPLong
by MandeepSinghKohli
Ircon International Ltd - Breakout Setup, Move is ON...#IRCON trading above Resistance of 298 Next Resistance is at 423 Support is at 211 Here are previous charts: Chart is self explanatory. Levels of breakout, possible up-moves (where stock may find resistances) and support (close below which, setup will be invalidated) are clearly defined. Disclaimer: This is for demonstration and educational purpose only. This is not buying or selling recommendations. I am not SEBI registered. Please consult your financial advisor before taking any trade.
NSE:IRCONLong
by MandeepSinghKohli
6
Glenmark Pharmaceuticals Limited - Breakout Setup, Move is ON...#GLENMARK trading above Resistance of 1262 Next Resistance is at 1943 Support is at 970 Here are previous charts: Chart is self explanatory. Levels of breakout, possible up-moves (where stock may find resistances) and support (close below which, setup will be invalidated) are clearly defined. Disclaimer: This is for demonstration and educational purpose only. This is not buying or selling recommendations. I am not SEBI registered. Please consult your financial advisor before taking any trade.
NSE:GLENMARKLong
by MandeepSinghKohli
Dr. Reddy's Laboratories Limited - Breakout Setup, Move is ON...#DRREDDY trading above Resistance of 6474 Next Resistance is at 7803 Support is at 5786 Here are previous charts: Chart is self explanatory. Levels of breakout, possible up-moves (where stock may find resistances) and support (close below which, setup will be invalidated) are clearly defined. Disclaimer: This is for demonstration and educational purpose only. This is not buying or selling recommendations. I am not SEBI registered. Please consult your financial advisor before taking any trade.
NSE:DRREDDYLong
by MandeepSinghKohli
Zydus Lifesciences Ltd - Breakout Setup, Move is ON...#ZYDUSLIFE trading above Resistance of 1128 Next Resistance is at 1297 Support is at 919 Here are previous charts: Chart is self explanatory. Levels of breakout, possible up-moves (where stock may find resistances) and support (close below which, setup will be invalidated) are clearly defined. Disclaimer: This is for demonstration and educational purpose only. This is not buying or selling recommendations. I am not SEBI registered. Please consult your financial advisor before taking any trade.
NSE:ZYDUSLIFELong
by MandeepSinghKohli
Kirloskar Brothers Limited - Breakout Setup, Move is ON...#KIRLOSBROS trading above Resistance of 2587 Next Resistance is at 2997 Support is at 1786 Here are previous charts: Chart is self explanatory. Levels of breakout, possible up-moves (where stock may find resistances) and support (close below which, setup will be invalidated) are clearly defined. Disclaimer: This is for demonstration and educational purpose only. This is not buying or selling recommendations. I am not SEBI registered. Please consult your financial advisor before taking any trade.
NSE:KIRLOSBROSLong
by MandeepSinghKohli
Marksans Pharma Ltd - Breakout Setup, Move is ON...#MARKSANS trading above Resistance of 180 Next Resistance is at 212 Support is at 134 Here are previous charts: Chart is self explanatory. Levels of breakout, possible up-moves (where stock may find resistances) and support (close below which, setup will be invalidated) are clearly defined. Disclaimer: This is for demonstration and educational purpose only. This is not buying or selling recommendations. I am not SEBI registered. Please consult your financial advisor before taking any trade.
NSE:MARKSANSLong
by MandeepSinghKohli
JD.com (JD): Key Levels to Watch for Potential ReversalJD.com has seen the expected drop towards the High Volume Node and Point of Control (POC) on the daily and three-day charts, between $27.50 and $26.80. Now, the price is falling further, and we think the lowest it could go is $24.65. This area is about $1 wide, and if it goes below that, it might drop to $20. Current Situation: The current situation shows the main support levels between $27.50 and $26.80. We believe the maximum downside is around $24.65. If it drops below this level, it could fall to $20. This support area is important because a lot of trading happened here, so it’s a key level to watch. Possible Scenarios: There are two possible scenarios: a continued decline or a bullish reversal. If the price keeps dropping, it's best to wait until we see some signs of strength. If it falls below $24.65, it could go down to $20. For the price to go up again, JD.com needs to get back above the resistance between $35 and $38. This would show a possible upward trend. Strategy: Our plan is to wait to see if the price shows some strength in the current support area. If it keeps falling, we should avoid entering the market. We need to keep an eye on the $24.65 level for any signs of a bigger drop. Also, watch if the price goes back above $35-$38 to signal a possible upward move. We are closely watching the current support area and will wait for signs of strength before making any decisions. We won't be catching falling knives at the moment, and if the price drops below $24.65, we expect it to fall towards $20. On the other hand, if it goes above $35-$38, it might start a bullish trend.
NASDAQ:JDLong
by freeguy_by_wmc
Adobe - Preparing a multi year breakout!NASDAQ:ADBE has been consolidating for some time and is definitely ready for a breakout. Adobe is a stock, which is clearly heading higher on a macro perspective. Just two months ago, Adobe actually retested an important horizontal structure and managed to create bullish confirmation, followed by a reversal towards the upside. Eventually, Adobe will also break out of the ascending triangle formation, which has been forming over the past 5 years. Levels to watch: $650 Keep your long term vision, Philip - BasicTrading
NASDAQ:ADBELong
by basictradingtv
Nurix Therapeutics (NRIX) Analysis Clinical Milestone: Nurix Therapeutics NASDAQ:NRIX , a clinical-stage biotech company, achieved a significant milestone with its NX-5948 leukemia drug, showing a 69.2% positive response in a trial for relapsed or refractory chronic lymphocytic leukemia (CLL). Needham analyst Gil Blum praised these results as a "clear win." Strategic Collaborations: Nurix is also advancing collaborations with major pharma companies. It is set to nominate a development candidate with Sanofi this year, positioning it for substantial breakthroughs. Additionally, Gilead Sciences extended its research collaboration with Nurix by two years, highlighting Nurix's robust R&D capabilities. Investment Outlook: Bullish Outlook: We are bullish on NRIX above the $15.00-$16.00 range. Upside Potential: With a target set at $30.00-$31.00, investors should consider Nurix's promising clinical results and strategic partnerships as key drivers for potential stock growth. 📊🧬 Monitor Nurix Therapeutics for promising investment opportunities! #NRIX #Biotech 📈💊
NASDAQ:NRIXLong
by Richtv_official